stockrow
Friday 6 November 2026
Export IRWD’s income statement to Excel — free account
Ironwood Pharmaceuticals, Inc.
IRWD Healthcare Drug Manufacturers Specialty & Generic
Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024.
- Revenue
- +9.00%
- EPS
- +45.2%
- Free cash flow
- +41.7%
- Total debt
- −44.4%
Quarter to September 2026, against a year earlier
4.36
0.33
+8.19%
Follow IRWD
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
4.36 | 5.28 | 5.51 | 21.38 |
+8 more quarters Free account |
P/S ratio |
1.64 | 1.78 | 1.59 | 1.84 | |
P/FCF ratio |
3.19 | 3.73 | 5.11 | 4.29 | |
P/Operating CF |
11.23 | 11.88 | 112.03 | 7.31 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.73 | 3.08 | 2.59 | 3.09 | |
EV/EBITDA |
4.31 | 5.08 | 4.64 | 9.11 | |
EV/Operating CF |
5.32 | 6.46 | 8.36 | 7.20 | |
EV/FCF |
5.32 | 6.46 | 8.36 | 7.20 | |
Quick Ratio |
6.31 | 5.84 | 1.38 | 1.08 | |
Current Ratio |
6.51 | 6.06 | 1.41 | 1.13 | |
Net Debt/EBITDA |
0.00 | 3.83 | 4.99 | 50.82 | |
Debt/Assets |
111.84% | 135.03% | 134.58% | 147.31% | |
Debt/Equity |
(3.34) | (2.38) | (2.69) | (2.23) | |
Asset Turnover |
1.17 | 1.24 | 0.95 | 0.79 | |
Operating CF/Net income |
0.00 | 1.14 | 0.13 | (32.77) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
15.03 | 11.01 | 7.94 | 0.86 | |
Research and Development Expense of Revenue |
21.31% | 19.83% | 20.60% | 45.83% | |
Selling, General and Administrative Expense of Revenue |
8.68% | 10.01% | 11.30% | 40.44% | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.00 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 2.86% | 3.43% | 8.01% | |
Graham Net Nets |
(0.25) | (0.36) | (0.56) | (0.71) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
22.93% | 18.95% | 18.17% | 4.68% | |
Free Cash Flow Yield |
31.37% | 26.80% | 19.55% | 23.29% | |
Revenue per Share |
0.81 | 0.69 | 0.65 | 0.29 | |
Operating CF per Share |
0.00 | 0.35 | 0.03 | 0.46 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.35 | 0.03 | 0.46 | |
Cash per Share |
0.52 | 0.48 | 1.35 | 1.33 | |
Shareholders Equity per Share |
(0.59) | (0.98) | (1.33) | (1.62) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.59) | (0.98) | (1.33) | (1.62) | |
Free Cash Flow |
67.40 | 58.28 | 5.12 | 74.58 | |
Working Capital |
191.26 | 166.35 | 95.99 | 31.96 | |
Capital Expenditures |
— | — | — | 0.00 | |
Net Current Asset Value |
(161.79) | (247.77) | (319.42) | (384.56) | |
EV/EBIT |
4.34 | 5.12 | 4.69 | 9.29 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
2.60 | 2.96 | 2.87 | 5.54 | |
| Other line items | |||||
Average Receivables |
126.54 | 99.45 | 72.81 | 64.32 | |
Average Payables |
2.61 | 1.15 | 4.53 | 2.51 | |
Average Assets |
343.33 | 314.04 | 380.89 | 373.90 | |
Average Common Equity |
(180.67) | (235.00) | (275.60) | (281.58) |
Columns are period end dates · fundamentals updated 6 Nov 2026